Top Markets
#1 Black Phoenix Black Phoenix +743.63%
#2 Islamic Coin Islamic Coin +146.07%
#3 Beam Beam +32.83%
#4 THORChain THORChain +25.51%
#5 TENDIES TENDIES +19.49%
#6 THORChain Yield THORChain Yield +19.43%
#7 SAFEcoin SAFEcoin +18.45%
#8 MiL.k Alliance MiL.k Alliance +16.38%
#9 Wrapped STX (Velar) Wrapped STX (Velar) +16.02%
#10 Bless Bless +15.60%
Coin of the day
Black Phoenix Black Phoenix
Settings
Language
ENGLISH
Currency
USD
Theme
Aerovate Therapeutics, Inc. Aerovate Therapeutics, Inc.

Aerovate Therapeutics, Inc.

AVTE
Rank in Stocks #5459
Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise... Aerovate Therapeutics, Inc. is a clinical-stage biopharmaceutical enterprise focused on innovating therapies to enhance the well-being of patients afflicted with rare cardiopulmonary illnesses across the United States. The company's principal effort involves advancing AV-101, an inhaled dry powder variant of imatinib, which is currently undergoing a Phase 2b/Phase 3 clinical study for the management of pulmonary arterial hypertension. Established in 2018, Aerovate Therapeutics, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Share Price
$93.80
Last synced: 2025-04-28
Market Cap
$2.68B
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade Aerovate Therapeutics, Inc. (AVTE)

Category

Healthcare
P/E ratio for Aerovate Therapeutics, Inc. (AVTE)
P/E ratio as of August 2026 TTM: 0.00
According to Aerovate Therapeutics, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0.00. At the end of 2023 the company had a P/E ratio of -7.89.
P/E ratio history for Aerovate Therapeutics, Inc. from 2020 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
2026 (TTM) 0.00 -100.00%
2024 -806.13 10,116.78%
2023 -7.89 -43.32%
2022 -13.92 11.07%
2021 -12.53 -78.39%
2020 -57.98 0.00%
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -4,171,571.43%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -4,374,271.43%
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 1,133,442.86%
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -4,637,371.43%
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.